v3.24.0.1
Consolidated Statements of Series A Preferred Shares and Shareholders' Equity - USD ($)
$ in Thousands
Total
At-The-Market Equity Program [Member]​
GSK Collaboration Agreement [Member]
Series A Preferred Shares [Member]
Ordinary Shares [Member]
Ordinary Shares [Member]
At-The-Market Equity Program [Member]​
Ordinary Shares [Member]
GSK Collaboration Agreement [Member]
Additional Paid-In-Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2021 $ 32,498       $ 749,851     $ 87,980 $ 181 $ (805,514)
Beginning balance, shares at Dec. 31, 2021         59,841,116          
Temporary equity, Beginning balance at Dec. 31, 2021       $ 7,874            
Temporary equity, Beginning balance, shares at Dec. 31, 2021       3,901,348            
Issuance of ordinary shares 51,220 $ 1,167     $ 51,220 $ 1,167        
Issuance of ordinary shares, shares   458,092     25,464,483 458,092        
Issuance of pre-funded warrants, net of offering costs 14,268             14,268    
Share-based compensation 17,194             17,194    
Vesting of RSUs, shares         904,891          
Option exercises 223       $ 223          
Option exercises, shares         90,000          
Issuance of ordinary shares under the ESPP 372       $ 372          
Issuance of ordinary shares under ESPP, shares         166,061          
Other comprehensive loss (210)               (210)  
Net Income (Loss) (161,823)                 (161,823)
Ending balance at Dec. 31, 2022 (45,091)       $ 802,833     119,442 (29) (967,337)
Ending balance, shares at Dec. 31, 2022         86,924,643          
Temporary equity, Ending balance at Dec. 31, 2022 $ 7,874     $ 7,874            
Temporary equity, Ending balance, shares at Dec. 31, 2022 3,901,348     3,901,348            
Issuance of ordinary shares $ 93,574 $ 3,080 $ 34,623   $ 93,574 $ 3,080 $ 34,623      
Issuance of ordinary shares, shares   751,688     20,000,000 751,688 10,683,761      
Share-based compensation 9,795             9,795    
Vesting of RSUs, shares         415,658          
Option exercises $ 509       $ 509          
Option exercises, shares 160,571       160,571          
Issuance of ordinary shares under the ESPP $ 748       $ 748          
Issuance of ordinary shares under ESPP, shares         225,913          
Other comprehensive loss (95)               (95)  
Net Income (Loss) (57,513)                 (57,513)
Ending balance at Dec. 31, 2023 39,630       $ 935,367     $ 129,237 $ (124) $ (1,024,850)
Ending balance, shares at Dec. 31, 2023         119,162,234          
Temporary equity, Ending balance at Dec. 31, 2023 $ 7,874     $ 7,874            
Temporary equity, Ending balance, shares at Dec. 31, 2023 3,901,348     3,901,348